JP2012131811A5 - - Google Patents

Download PDF

Info

Publication number
JP2012131811A5
JP2012131811A5 JP2012034259A JP2012034259A JP2012131811A5 JP 2012131811 A5 JP2012131811 A5 JP 2012131811A5 JP 2012034259 A JP2012034259 A JP 2012034259A JP 2012034259 A JP2012034259 A JP 2012034259A JP 2012131811 A5 JP2012131811 A5 JP 2012131811A5
Authority
JP
Japan
Prior art keywords
vomiting
emesis
nausea
palonosetron
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012034259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012131811A (ja
JP5893950B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012131811A publication Critical patent/JP2012131811A/ja
Publication of JP2012131811A5 publication Critical patent/JP2012131811A5/ja
Application granted granted Critical
Publication of JP5893950B2 publication Critical patent/JP5893950B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2012034259A 2002-11-15 2012-02-20 化学療法誘導嘔吐を治療するためのパロノセトロン Expired - Lifetime JP5893950B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42682902P 2002-11-15 2002-11-15
US60/426,829 2002-11-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004553037A Division JP5690461B2 (ja) 2002-11-15 2003-11-06 化学療法誘導嘔吐を治療するためのパロノセトロン

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015086840A Division JP2015143266A (ja) 2002-11-15 2015-04-21 化学療法誘導嘔吐を治療するためのパロノセトロン

Publications (3)

Publication Number Publication Date
JP2012131811A JP2012131811A (ja) 2012-07-12
JP2012131811A5 true JP2012131811A5 (OSRAM) 2014-04-17
JP5893950B2 JP5893950B2 (ja) 2016-03-23

Family

ID=32326433

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2004553037A Expired - Lifetime JP5690461B2 (ja) 2002-11-15 2003-11-06 化学療法誘導嘔吐を治療するためのパロノセトロン
JP2012034259A Expired - Lifetime JP5893950B2 (ja) 2002-11-15 2012-02-20 化学療法誘導嘔吐を治療するためのパロノセトロン
JP2015086840A Pending JP2015143266A (ja) 2002-11-15 2015-04-21 化学療法誘導嘔吐を治療するためのパロノセトロン
JP2016162972A Expired - Lifetime JP6342960B2 (ja) 2002-11-15 2016-08-23 化学療法誘導嘔吐を治療するためのパロノセトロン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004553037A Expired - Lifetime JP5690461B2 (ja) 2002-11-15 2003-11-06 化学療法誘導嘔吐を治療するためのパロノセトロン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015086840A Pending JP2015143266A (ja) 2002-11-15 2015-04-21 化学療法誘導嘔吐を治療するためのパロノセトロン
JP2016162972A Expired - Lifetime JP6342960B2 (ja) 2002-11-15 2016-08-23 化学療法誘導嘔吐を治療するためのパロノセトロン

Country Status (6)

Country Link
US (2) US20060079545A1 (OSRAM)
JP (4) JP5690461B2 (OSRAM)
AU (1) AU2003302072A1 (OSRAM)
CA (1) CA2505990C (OSRAM)
DE (1) DE10393729T5 (OSRAM)
WO (1) WO2004045615A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4704755B2 (ja) * 2002-11-05 2011-06-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗菌剤
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
NZ576237A (en) * 2006-10-24 2011-12-22 Helsinn Healthcare Sa Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
US20100105724A1 (en) * 2006-12-07 2010-04-29 Helsinn Healthcare Sa Crystalline and amorphous forms of palonosetron hydrochloride
ES2604968T3 (es) * 2008-04-28 2017-03-10 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
EP2286814B1 (en) 2008-05-15 2013-10-16 Hisamitsu Pharmaceutical Co., Inc. Transdermal preparation containing palonosetron
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
US20100143461A1 (en) * 2008-12-08 2010-06-10 Ben-Zion Solomon Palonosetron formulation
US20120253046A1 (en) 2009-11-13 2012-10-04 Helsinn Healthcare S.A. Palonosetron metabolites
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
RS53491B1 (sr) 2009-11-18 2015-02-27 Helsinn Healthcare Sa Kompozicije za lečenje centralno posredovane mučnine i povraćanja
WO2016118540A1 (en) * 2015-01-20 2016-07-28 Xoc Pharmaceuticals, Inc. Treating and/or preventing emesis and/or nausea including acute and/or delayed nausea and/or emesis
JP6642377B2 (ja) * 2016-10-25 2020-02-05 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US807381A (en) * 1905-01-10 1905-12-12 Auto Stopper Company Means for securing stoppers for vessels in their caps.
US1796729A (en) * 1930-04-18 1931-03-17 Aluminum Co Of America Closure
US2069075A (en) * 1934-04-20 1937-01-26 United Dairies London Ltd Bottle or like container
US2113176A (en) * 1936-03-26 1938-04-05 Guardian Safety Seal Company Sealed receptacle
US3314564A (en) * 1965-05-06 1967-04-18 West Co Container closure
US3601273A (en) * 1969-01-31 1971-08-24 Aluminum Co Of America Pilferproof closure with vertical weakening lines
DE2315962A1 (de) * 1972-04-05 1973-10-18 Metal Closures Ltd Verschlusskappenrohling fuer flaschen od. dgl.
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
EP0200444B1 (en) * 1985-04-27 1992-11-11 Beecham Group Plc Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
KR970007917B1 (ko) * 1989-11-28 1997-05-17 신텍스 인크. 신규 삼환식 화합물
GB2277749B (en) * 1993-05-08 1996-12-04 Ciba Geigy Ag Fluorescent whitening of paper
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
US20030127420A1 (en) * 2002-01-09 2003-07-10 Klaus Schumacher Dual bottle closure
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting

Similar Documents

Publication Publication Date Title
JP2012131811A5 (OSRAM)
CN111065639A (zh) 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
MX2020003381A (es) Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma.
SA522432668B1 (ar) طرق لعلاج سرطان الرئة للخلايا الصغيرة بصيغ من لوربينيكتيدين
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
AR095338A1 (es) Método de tratamiento no tóxico para la abstinencia de drogas
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
RU2017134443A (ru) Способ лечения с применением традипитанта
JP2019511496A5 (OSRAM)
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
MX2022005596A (es) Regimen de dosificacion para agentes anti-dll3.
JP2016509050A5 (OSRAM)
JP2019530706A5 (OSRAM)
MX389336B (es) Formulacion farmaceutica.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
JP2018506533A5 (OSRAM)
AR088453A1 (es) Regimen de dosificacion del agonista o modulador del receptor de s1p
JP2014502608A5 (OSRAM)
MX2020011471A (es) R-fadrozol para usar en el tratamiento de aldosteronismo.
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
MX393290B (es) Composicion para el tratamiento de la osteoartritis
IL275091B2 (en) Methods for treating gaucher disease
RU2013126798A (ru) Комбинированная терапия дексаметазоном